{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:19:39Z","timestamp":1789503579565,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,14]]},"DOI":"10.7759\/cureus.84129","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:42:32Z","timestamp":1747269752000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mar\u00eda Victoria","family":"Santos Guzm\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daimi","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Marian","family":"Reyna Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfida Luisa","family":"Fernandez Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Azcona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Escobar Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Montano Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Carlos","family":"Garc\u00eda Zuluaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Santos Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10385-y","article-title":"Heart failure with mildly reduced and preserved ejection fraction: a review of disease burden and remaining unmet medical needs within a new treatment landscape","volume":"29","author":"Desai N","year":"2024","unstructured":"Desai N, Olewinska E, Famulska A, Remuzat C, Francois C, Folkerts K. Heart failure with mildly reduced and preserved ejection fraction: a review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Fail Rev. 2024, 29:631-62. 10.1007\/s10741-024-10385-y","journal-title":"Heart Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.13","article-title":"The therapy and management of heart failure with preserved ejection fraction: new insights on treatment","volume":"10","author":"Balestrieri G","year":"2024","unstructured":"Balestrieri G, Limonta R, Ponti E, et al.. The therapy and management of heart failure with preserved ejection fraction: new insights on treatment. Card Fail Rev. 2024, 10:e05. 10.15420\/cfr.2023.13","journal-title":"Card Fail Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2018.76279","article-title":"Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview","volume":"14","author":"Michalska-Kasiczak M","year":"2018","unstructured":"Michalska-Kasiczak M, Bielecka-Dabrowa A, von Haehling S, Anker SD, Rysz J, Banach M. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Arch Med Sci. 2018, 14:890-909. 10.5114\/aoms.2018.76279","journal-title":"Arch Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15090","article-title":"Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities","volume":"12","author":"D'Italia G","year":"2025","unstructured":"D'Italia G, Schroen B, Cosemans JM. Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities. ESC Heart Fail. 2025, 12:1013-28. 10.1002\/ehf2.15090","journal-title":"ESC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-023-10324-3","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews","volume":"28","author":"Karakasis P","year":"2023","unstructured":"Karakasis P, Pamporis K, Stachteas P, Patoulias D, Bougioukas KI, Fragakis N. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews. Heart Fail Rev. 2023, 28:1033-51. 10.1007\/s10741-023-10324-3","journal-title":"Heart Fail Rev"},{"key":"ref6","unstructured":"Risk of bias tools - Current version of RoB 2. (2019). https.\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/current-version-of-rob-2."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12707","article-title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)","volume":"7","author":"Tanaka A","year":"2020","unstructured":"Tanaka A, Hisauchi I, Taguchi I, et al.. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC Heart Fail. 2020, 7:1585-94. 10.1002\/ehf2.12707","journal-title":"ESC Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial","volume":"44","author":"B\u00f6hm M","year":"2023","unstructured":"B\u00f6hm M, Anker S, Mahfoud F, et al.. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. 2023, 44:396-407. 10.1093\/eurheartj\/ehac693","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156309","article-title":"SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?","volume":"131","author":"Echouffo-Tcheugui JB","year":"2021","unstructured":"Echouffo-Tcheugui JB, Lewsey SC, Weiss RG. SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?. J Clin Invest. 2021, 131:10.1172\/JCI156309","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.04.019","article-title":"Chapter 3: Clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure","volume":"137","author":"Greene SJ","year":"2024","unstructured":"Greene SJ, Butler J, Kosiborod MN. Chapter 3: Clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure. Am J Med. 2024, 137:S25-34. 10.1016\/j.amjmed.2023.04.019","journal-title":"Am J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-087617","article-title":"Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial","volume":"14","author":"Yan H","year":"2024","unstructured":"Yan H, Wang W, Li Y, et al.. Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open. 2024, 14:e087617. 10.1136\/bmjopen-2024-087617","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/17539447241289067","article-title":"Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Hamid AK","year":"2024","unstructured":"Hamid AK, Tayem AA, Al-Aish ST, Al Sakini AS, Hadi DD, Al-Aish RT. Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Ther Adv Cardiovasc Dis. 2024, 18:17539447241289067. 10.1177\/17539447241289067","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1046194","article-title":"Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: an updated systematic review and meta-analysis","volume":"10","author":"Treewaree S","year":"2023","unstructured":"Treewaree S, Kulthamrongsri N, Owattanapanich W, Krittayaphong R. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: an updated systematic review and meta-analysis. Front Cardiovasc Med. 2023, 10:1046194. 10.3389\/fcvm.2023.1046194","journal-title":"Front Cardiovasc Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac779.040","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis","volume":"44","author":"Cordovez R a B","year":"2023","unstructured":"Cordovez R a B, Rivera KA, Denila RW, Patricio MD. Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis. Eur Heart J. 2023, 44:10.1093\/eurheartj\/ehac779.040","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwac056.020","article-title":"SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis","volume":"29","author":"Tsampasian V","year":"2022","unstructured":"Tsampasian V, Elghazaly H, Chattopadhyay R, et al.. SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis. Eur J Prevent Cardiol. 2022, 29:10.1093\/eurjpc\/zwac056.020","journal-title":"Eur J Prevent Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.875327","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials","volume":"9","author":"Zhou H","year":"2022","unstructured":"Zhou H, Peng W, Li F, et al.. Effect of sodium-glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2022, 9:875327. 10.3389\/fcvm.2022.875327","journal-title":"Front Cardiovasc Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2023.03.003","article-title":"SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis","volume":"75","author":"Banerjee M","year":"2023","unstructured":"Banerjee M, Pal R, Nair K, Mukhopadhyay S. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis. Indian Heart J. 2023, 75:122-7. 10.1016\/j.ihj.2023.03.003","journal-title":"Indian Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.19080\/jocct.2023.18.555990","article-title":"Looking at the efficacy of SGLT2 inhibitors in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Menon T","year":"2023","unstructured":"Menon T. Looking at the efficacy of SGLT2 inhibitors in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis. J Cardiol Cardiovasc Ther. 2023, 18:10.19080\/jocct.2023.18.555990","journal-title":"J Cardiol Cardiovasc Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01283-6","article-title":"Systematic review of the economic evaluation of sodium-glucose cotransporter-2 inhibitors used as treatment in patients with heart failure","volume":"43","author":"Nam K","year":"2023","unstructured":"Nam K, Cho DS, Kim H, et al.. Systematic review of the economic evaluation of sodium-glucose cotransporter-2 inhibitors used as treatment in patients with heart failure. Clin Drug Investig. 2023, 43:463-74. 10.1007\/s40261-023-01283-6","journal-title":"Clin Drug Investig"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.752370","article-title":"Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"12","author":"Pabel S","year":"2021","unstructured":"Pabel S, Hamdani N, Singh J, Sossalla S. Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction. Front Physiol. 2021, 12:752370. 10.3389\/fphys.2021.752370","journal-title":"Front Physiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey AK","year":"2023","unstructured":"Pandey AK, Bhatt DL, Pandey A, Marx N, Cosentino F, Pandey A, Verma S. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023, 44:3640-51. 10.1093\/eurheartj\/ehad389","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2022-7-1","article-title":"Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction","volume":"12","author":"De Lorenzi AB","year":"2023","unstructured":"De Lorenzi AB, Kaplinsky E, Zambrano MR, Chaume LT, Rosas JM. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. Drugs Context. 2023, 12:10.7573\/dic.2022-7-1","journal-title":"Drugs Context"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366901-efficacy-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:42:34Z","timestamp":1747269754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366901-efficacy-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.84129","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}